MIRM News and Press, Mirum Pharmaceuticals Inc. From 10/13/23

2023-10-13 17:12:53 ET More on Mirum Pharmaceuticals Mirum Pharmaceuticals: An Attractive Stock To Watch For Its Liver Disease Franchise Seeking Alpha’s Quant Rating on Mirum Pharmaceuticals For further details see: Mirum Pharmaceuticals to sell 7.94M shar...

- LIVMARLI PFIC primary analysis from MARCH study awarded prestigious Gerard Odell Prize for Excellence in Pediatric Hepatology Research - 15 abstracts demonstrating robust clinical findings from LIVMARLI studies and real-world experience in ALGS and PFIC Mirum Pharmaceuticals...

- Primary endpoint met (p<0.0001); 20-fold difference in urine bile alcohols - First and only prospective, controlled clinical trial in CTX - Plasma cholestanol endpoint met (p=0.0083), the driver of poor outcomes in CTX patients - Data to be submitted for presentatio...

- 15 abstracts accepted for presentation showcasing LIVMARLI data from ALGS and PFIC programs - LIVMARLI PFIC primary analysis from MARCH study awarded prestigious Gerard Odell Prize for Excellence in Pediatric Hepatology Research Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) tod...

2023-09-24 03:51:29 ET Summary Mirum Pharmaceuticals has two drugs, maralixibat and volixibat, targeting rare liver diseases involving cholestasis. The company's lead program, maralixibat, was approved for Alagille syndrome and has a busy data drop schedule for label expansions. ...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it is scheduled to participate in a fireside chat at the 2023 Ca...

2023-09-14 11:46:59 ET More on Mirum Pharmaceuticals Seeking Alpha’s Quant Rating on Mirum Pharmaceuticals Historical earnings data for Mirum Pharmaceuticals Financial information for Mirum Pharmaceuticals Mirum Pharmaceuticals, Inc. ( NASDAQ: MIRM...

2023-09-11 10:13:06 ET More on Mirum Pharmaceuticals Seeking Alpha’s Quant Rating on Mirum Pharmaceuticals Historical earnings data for Mirum Pharmaceuticals Financial information for Mirum Pharmaceuticals Mirum: Must Watch Biotech On Release Of Result...

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced the appointment of Eric Bjerkholt as chief financial officer (CFO). “Eric is an accomplished CFO bringing an outstanding track record in driving financial performance, business development, and operations management,” sa...

Mirum has acquired Travere’s rights and assets related to Cholbam ® and Chenodal ® Travere received $210 million at closing and is eligible for up to $235 million in potential sales-based milestone payments Expands Mirum’s leadership in rare liver disea...